Page last updated: 2024-11-06

n-acetylglutamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-acetylglutamic acid (NAG) is a key cofactor in the urea cycle, a metabolic pathway that removes ammonia from the body. It is synthesized in the liver by the enzyme N-acetylglutamate synthase (NAGS) and acts as an allosteric activator of carbamoyl phosphate synthetase I (CPS I), the first enzyme in the urea cycle. NAG increases the affinity of CPS I for its substrate, carbamoyl phosphate, and stimulates the activity of the enzyme. Deficiency of NAG leads to hyperammonemia, a dangerous condition where ammonia accumulates in the blood. NAG is also involved in other metabolic pathways, such as the biosynthesis of arginine and the regulation of gluconeogenesis. The role of NAG in these pathways is under investigation, and further research is needed to fully understand its significance in human health. NAG is studied to understand its role in ammonia detoxification and the regulation of metabolism, as well as to develop potential therapeutic applications for hyperammonemia and other metabolic disorders.'

N-acetylglutamic acid: RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-acetyl-L-glutamic acid : An N-acyl-L-amino acid that is L-glutamic acid in which one of the amine hydrogens is substituted by an acetyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID70914
CHEMBL ID1234751
CHEBI ID17533
SCHEMBL ID82128
MeSH IDM0066026

Synonyms (102)

Synonym
bdbm50151383
CHEMBL1234751
AKOS015837749
(s)-2-(acetylamino)pentanedioic acid
n-ac-glu-oh
acetyl-l-glutamic acid
n-acetylglutamic acid
CHEBI:17533 ,
ac-glu-oh
l-n-acetylglutamic acid
(2s)-2-acetamidopentanedioic acid
acetylglutamic acid
KBIO1_000406
DIVK1C_000406
SPECTRUM_000981
l-glutamic acid, n-acetyl-
einecs 214-708-4
acetyl glutamic acid
glutamic acid, n-acetyl-, l-
glutamic acid, n-acetyl- (6ci,7ci)
n-acetylglutamate
IDI1_000406
SPECTRUM5_001040
BSPBIO_003014
NLG ,
inchi=1/c7h11no5/c1-4(9)8-5(7(12)13)2-3-6(10)11/h5h,2-3h2,1h3,(h,8,9)(h,10,11)(h,12,13)/t5-/m0/s
n-acetyl-l-glutamic acid
n-acetyl-l-glutamate
1188-37-0
C00624
n-acetyl-l-glutamic acid, reagentplus(r), 99%
NCGC00166080-01
DB04075
KBIO2_001461
KBIOSS_001461
KBIO2_006597
KBIO3_002234
KBIOGR_001324
KBIO2_004029
SPECTRUM3_001397
SPBIO_001537
SPECTRUM2_001349
NINDS_000406
SPECTRUM4_000892
SPECTRUM1500703
NCGC00166080-02
17A85284-85CE-4442-B1DA-2E5EE18AA75F
A0693
glutamic acid, n-acetyl-, l- (8ci)
BMSE000382
HMS501E08
HMS1921E14
A804116
tox21_112308
dtxsid3046534 ,
dtxcid1026534
cas-1188-37-0
CCG-39287
ma61h539yz ,
unii-ma61h539yz
ec 214-708-4
acetylglutamate
S6245
SCHEMBL82128
AM81692
tox21_112308_1
NCGC00094839-04
n-acetyl-s-glutamic acid
fema no. 4752
.alpha.-(n-acetyl)-l-glutamic acid
acetyl glutamic acid [inci]
n-acetyl glutamic acid
n-ac-l-glu
n-acetyl-l-glutamicacid
Q-100087
n-acetylglutamic acid #
AC-24110
(2s)-2-acetamidoglutaric acid
J-523434
n-acetyl-l-glu
EN300-881279
n-acetyl-l-glutamic acid, vetec(tm) reagent grade, 99%
ac-glu
2-acetamido-l-glutaraldehydate
n-acetyl l-glutamate
n-acetyl-glutamic acid
n-acetyl-l-glutamic acid-gamma-semialdehyde
n-acetylglutamic gamma-semialdehyde
2-acetamido-l-glutaraldehydic acid
acetyl-glutamate
n-acetyl-dl-glutamate
dl-acetylglutamate
n-acetyl l-glutamic acid
n-acetyl-glutamate
Q63390524
(s)-2-acetamidopentanedioic acid
AS-12953
AC9784
HY-W015240
CS-W015956
ac-l-glu-oh
Z98654650

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No mortalities or evidence of adverse effects was observed in Sprague-Dawley rats following acute oral gavage with NAG at a dose of 2000 mg/kg of body weight."( N-acetyl-glutamic acid: evaluation of acute and 28-day repeated dose oral toxicity and genotoxicity.
Amanda Shen, Z; Barnett, JF; Delaney, B; Harper, MS; Krsmanovic, L; Myhre, A, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
N-acetyl-L-amino acidAn L-amino acid having an N-acetyl substituent.
N-acyl-L-glutamic acidAny optically active N-acylglutamic acid having L-configuration.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Metabolism14961108
Amino acid and derivative metabolism250260
Urea cycle822
Urea cycle and metabolism of amino groups2116
Arginine biosynthesis526
Arginine biosynthesis II (acetyl cycle)425
Ornithine biosynthesis216

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency24.54540.01237.983543.2770AID1645841
estrogen nuclear receptor alphaHomo sapiens (human)Potency29.84930.000229.305416,493.5996AID743079
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency28.18380.010323.856763.0957AID2662
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysine-specific demethylase 4CHomo sapiens (human)IC50 (µMol)2,070.00000.16002.11489.4000AID1282304
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Olfactory receptor 51E2Homo sapiens (human)EC50 (µMol)0.00020.00000.07800.5700AID1639697
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
adenylate cyclase-activating G protein-coupled receptor signaling pathwayOlfactory receptor 51E2Homo sapiens (human)
cell migrationOlfactory receptor 51E2Homo sapiens (human)
melanocyte differentiationOlfactory receptor 51E2Homo sapiens (human)
steroid hormone mediated signaling pathwayOlfactory receptor 51E2Homo sapiens (human)
positive regulation of blood pressureOlfactory receptor 51E2Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of smellOlfactory receptor 51E2Homo sapiens (human)
cellular response to fatty acidOlfactory receptor 51E2Homo sapiens (human)
melanocyte proliferationOlfactory receptor 51E2Homo sapiens (human)
positive regulation of renin secretion into blood streamOlfactory receptor 51E2Homo sapiens (human)
blastocyst formationLysine-specific demethylase 4CHomo sapiens (human)
positive regulation of cell population proliferationLysine-specific demethylase 4CHomo sapiens (human)
stem cell population maintenanceLysine-specific demethylase 4CHomo sapiens (human)
androgen receptor signaling pathwayLysine-specific demethylase 4CHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific demethylase 4CHomo sapiens (human)
regulation of androgen receptor signaling pathwayLysine-specific demethylase 4CHomo sapiens (human)
regulation of stem cell differentiationLysine-specific demethylase 4CHomo sapiens (human)
regulation of gene expressionLysine-specific demethylase 4CHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 4CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
nuclear steroid receptor activityOlfactory receptor 51E2Homo sapiens (human)
G protein-coupled receptor activityOlfactory receptor 51E2Homo sapiens (human)
olfactory receptor activityOlfactory receptor 51E2Homo sapiens (human)
signaling receptor activityOlfactory receptor 51E2Homo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4CHomo sapiens (human)
zinc ion bindingLysine-specific demethylase 4CHomo sapiens (human)
enzyme bindingLysine-specific demethylase 4CHomo sapiens (human)
nuclear receptor coactivator activityLysine-specific demethylase 4CHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 4CHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 4CHomo sapiens (human)
nuclear androgen receptor bindingLysine-specific demethylase 4CHomo sapiens (human)
histone H3K36 demethylase activityLysine-specific demethylase 4CHomo sapiens (human)
H3K9me3 modified histone bindingLysine-specific demethylase 4CHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
plasma membraneOlfactory receptor 51E2Homo sapiens (human)
early endosome membraneOlfactory receptor 51E2Homo sapiens (human)
intracellular organelleOlfactory receptor 51E2Homo sapiens (human)
plasma membraneOlfactory receptor 51E2Homo sapiens (human)
nucleoplasmLysine-specific demethylase 4CHomo sapiens (human)
chromatinLysine-specific demethylase 4CHomo sapiens (human)
pericentric heterochromatinLysine-specific demethylase 4CHomo sapiens (human)
nucleusLysine-specific demethylase 4CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1282304Inhibition of N-terminal His6-tagged KDM4C (1 to 352 residues) (unknown origin) expressed in Escherichia coli Rosetta 2(DE3)pLysS using biotinylated histone H3 (1 to 21 residues) lysine 9 trimethylated peptide/2 uM alpha-ketoglutarate as substrate/cofacto2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (186)

TimeframeStudies, This Drug (%)All Drugs %
pre-199077 (41.40)18.7374
1990's39 (20.97)18.2507
2000's27 (14.52)29.6817
2010's31 (16.67)24.3611
2020's12 (6.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.52 (24.57)
Research Supply Index5.25 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index43.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.07%)5.53%
Reviews7 (3.74%)6.00%
Case Studies3 (1.60%)4.05%
Observational0 (0.00%)0.25%
Other175 (93.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]